Diagnosis, treatment and prognosis of patients with synovial sarcoma: The Scandinavian Sarcoma Group experience

Acta Orthopaedica Scandinavica, Supplement

Volumn 70, Issue 285, 1999, Pages 47-49

  Skytting, Björn T ^a   Bauer, Henrik C F ^b   Larsson, Olle ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; SYNOVIAL SARCOMA; TUMOR VOLUME; AMPUTATION; ARTICLE; CONNECTIVE TISSUE TUMOR; DISCRIMINANT ANALYSIS; FOLLOW UP; GENE TRANSLOCATION; GENETICS; MORTALITY; NUCLEIC ACID HYBRIDIZATION; REGISTER; RISK FACTOR; SCANDINAVIA; SURVIVAL; TREATMENT OUTCOME;

DNA;

AMPUTATION; DISCRIMINANT ANALYSIS; DNA, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; REGISTRIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SARCOMA, SYNOVIAL; SCANDINAVIA; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 0033146641     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. Alvegård T A, Berg N O, Baldetorp B, Fernö M, Killander D, Ranstam J, Rydholm A, Åkerman M. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. Am J Clin Oncol 1990; 8: 538-17.
2. Cadman N L, Soule E H, Kelly P J. Synovial sarcoma. Cancer 1965; 18: 613-23.
3. Cagle L A, Mirra J M, Storm K, Roe D J, Eilber F R. Histologic Fetaures Relating to Prognosis in Synovial Sarcoma. Cancer 1987; 59: 1910-1814.
4. Choong P F M, Pritchard D J, Sim F H, Rock M G, Nascimento A G. Long-term survival in high grade soft tissue sarcoma: prognostic factors in synovial sarcoma. Int J Oncol 1995; 7: 161-9.
5. Clark J, Rocques P J, Crew A J, Gill S, Shipley J, Chan A M. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502-8.
6. Enzinger F M and Weiss S W. Soft Tissue Tumors. Mosby. St.Louis 1995.
7. el-Naggar A K, Ayala A G, Abdul-Karim F W, McLemore D, Ballance. Synovial sarcoma. A DNA flow cytometric study. Cancer 1990; 65: 2295-300.
8. Finlay C A, Hinds P W, Tan T H, Eliyahu D, Oren M, Levine A J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-9.
9. Hajdu S I, Shui M H, Fortner J G. Tendosynovial sarcoma. Cancer 1977; 39: 1201-17.
10. Gerdes J, Lemke H, Baisch H, Wacker H H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5.
11. Kawai A, Woodruff J, Healey J H, Brennan M, Antonescu C, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-60.
12. de Leeuw B, Balemans M, Weghuis D O, Seruca R, Janz M. Molecular cloning of the synovial sarcoma-specific translocation (X;18)(p11.2;q11.2) breakpoint. Hum Mol Genet 1994; 3: 745-9.
13. Moberger G, Nilsonne U, Friberg S. Synovial sarcoma. Acta Orthop Scand 1968; 111: 3-38.
14. Nigro J M, Baker S J, Preisinger A C, Jessup J M, Hostetter R, Cleary K, Bigner S H, Davidson N, Baylin S, Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature 1986; 342: 705-8.
15. Oda Y, Hashimoto H, Tsuneyoshi M, Takeshita S. Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol 1993; 17: 35-44.
16. Raycroft L, Wu H Y, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990; 249: 1049-51.
17. Singer S, Baldini E H, Demetri G D, Fletcher J A, Corson J M. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 1996; 14: 1201-8.
18. Turc-Carel C, Dal Cin P, Limon J, Rao U, Li R P, Corson J M, Zimmerman R, Parry M, Cowan J M, Sandberg A A. Proc Natl Acad Sci USA 1987; 84: 1981-5.
19. Wright P H, Sim F H, Soule E H, Taylor W F. Synovial sarcoma. J Bone Joint Surg Am 1982; 64: 112-22.
20. Yin Y, Tainsky M A, Bischoff F Z, Strong L C, Wahl G M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-48.